Epoch Biotech Highlights New Preclinical Data for APOE Christchurch-Mimetic Antibody at AAIC 2026 Demonstrating Favorable PK/PD and Differentiated Biomarker Approach

Conference7C11Positive

AI Analysis

Summary

Epoch Biotech presented preclinical data for 7C11, an APOE Christchurch-mimetic antibody, at AAIC 2026 demonstrating favorable pharmacokinetics and pharmacodynamics in non-human primates with effects on tau, amyloid, and brain vasculature biomarkers. The candidate has potential to address both familial and sporadic Alzheimer's disease.

Outcome Details

Preclinical data presented at AAIC 2026 showing favorable PK/PD and biomarker activity in non-human primates

Importance:5/10

Sentiment:

0.60

Alzheimer's diseaseAPOE Christchurch variantpreclinical dataantibodybiomarkerstauamyloidbrain vasculaturefamilial Alzheimer'ssporadic Alzheimer's

Related Companies

$BNN.DE

Read the original article

Published by GlobeNewswire Clinical Studies on July 15, 2026 7:00 AM

Read Original